Which methodologies are currently in place to analyze organizational value of health technologies? How can they be integrated and provide value for new approaches of personalized medicine? This session will review and analyse existing frameworks and values from the organisational perspective including EUnetHTA core Model, ADHopHTA and INTEGRATE-HTA framework.
Do they suffice to define the impact and the value Personalised medicine solutions (cell and gene therapies, CAR-Ts,…) could bring to the health care systems? Do we need to think about new frameworks and services? Are those frameworks applicable to all the countries and systems? Which are the challenges of applying personalised medicine technologies in LMIcs?